Genetic testing for common variation in skin cancer may be acceptable in the general population and addressing barriers to testing may be warranted, a new study found. The randomized clinical trial included 499 adult participants and examined interest in and uptake of MC1R testing for melanoma risk in a diverse primacy care population, including Hispanics. Participants were presented with the option to log onto the study website to read 3 educational modules presenting the rationale, benefits, and drawbacks of MC1R testing. Main outcomes included website log on, saliva test kit request, and saliva test kit return for MC1R testing. Researchers found:

• 499 participants were included (220 non-Hispanic white, 242 Hispanic, 396 female; mean age 54 years).
• Nearly half (46%) of participants logged onto the study website to consider testing.
• 204 (88%) of those who logged on decided to request testing.
• 167 (82%) of those who requested testing returned the kit.
• Non-Hispanic whites and those with higher educational attainment were most likely to be interested in testing, compared to Hispanics and those with lower educational attainment.